Associated Papers
Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.
Smith RA et al.
The Journal of Infectious Diseases, 2022
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T et al.
The Journal of Antimicrobial Chemotherapy, 2015
Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q et al.
Journal of Chemical Information and Modeling, 2013
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME et al.
Antimicrobial Agents and Chemotherapy, 2013
HIV Drug Resistance and the Advent of Integrase Inhibitors.
Quashie PK et al.
Current Infectious Disease Reports, 2013
Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL et al.
Intervirology, 2012
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O et al.
Virology, 2010
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M et al.
Antiviral Therapy, 2007
Select a paper to view details